上海科华生物工程股份有限公司 2022 年第一季度报告全文 | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2022-019 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 公司 2022 年 4 月 28 日召开第八届董事会第十六次会议，审议《关于控股子公司暂时失去控制且暂不纳入合并报表范围 的议案》，因天隆公司管理层违反本公司对控股子公司管理规章制度的规定，违反天隆公司《公司章程》规定，拒绝履行天 隆公司董事会做出的决议，拒绝配合本公司聘请的立信会计师事务所（特殊普通合伙）开展 2021 年度审计工作，公司目前 已经无法取得天隆公司的财务资料，无法掌握天隆公司的实际经营情况、资产状况及面临的风险等信息，公司对天隆公司的 管理控制无法得到天隆公司管理层的执行。公司董事会基于谨慎考虑，审议将天隆公司自 2021 年 10 月 1 日起暂不纳入公司 合并报表。 上海科华生物工程股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会 ...

上海科华生物工程股份有限公司 2021 年第三季度报告 | 证券代码：002022 | 证券简称：科华生物 | 公告编号：2021-094 | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | | 上海科华生物工程股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 1,327,832,849.51 | 19.93% | 3,727,801,760.84 | 45.19% | | 归属于上市公司股东的 | 250,039,443.94 | 19.54% | 729,089,582.16 | 81.44% | | 净利润（元） | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 251,215,709.56 | 22.19% | 723,898,9 ...

上海科华生物工程股份有限公司 2021 年半年度报告全文 上海科华生物工程股份有限公司 2021 年半年度报告 2021-078 2021 年 08 月 1 上海科华生物工程股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人周琴琴、主管会计工作负责人罗芳及会计机构负责人(会计主管 人员)许振中声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承诺， 投资者及相关人士应当对此保持足够的风险认识，并应当理解计划、预测与承 诺之间的差异。 本公司请投资者认真阅读本报告，公司在本报告第三节"管理层讨论与分 析"中"十、公司面临的风险及应对措施"部分，阐述了公司未来经营可能面临的 主要风险，敬请广大投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 | | ...

Financial Performance - Revenue for Q1 2021 reached ¥1,453,210,918.22, representing a 170.82% increase compared to ¥536,588,796.53 in the same period last year[8] - Net profit attributable to shareholders was ¥342,225,938.64, a significant increase of 584.50% from ¥49,996,448.89 year-on-year[8] - Net profit excluding non-recurring items was ¥340,651,901.14, up 636.54% from ¥46,250,398.68 in the previous year[8] - Basic earnings per share rose to ¥0.6717, a 588.92% increase from ¥0.0975 in the same period last year[8] - Diluted earnings per share increased to ¥0.6410, up 558.79% from ¥0.0973 year-on-year[8] - The total comprehensive income for the period was ¥521,524,387.68, compared to ¥81,775,983.57 in the previous year, showcasing strong financial performance[48] - The company reported a net profit of CNY 2,279,683,562.64 in retained earnings, up from CNY 1,937,457,624.00, indicating an increase of approximately 17.7%[40] - The net profit for the first quarter of 2021 was ¥19,601,954.15, a significant recovery from a net loss of ¥21,347,767.09 in the same period last year[50] - Operating profit reached ¥22,274,246.88, compared to an operating loss of ¥26,438,851.96 in the previous year[50] Cash Flow and Assets - Operating cash flow for the period was ¥352,209,941.61, reflecting a 535.18% increase compared to ¥55,450,002.38 in the same quarter last year[8] - Cash flow from operating activities amounted to ¥352,209,941.61, a substantial increase from ¥55,450,002.38 in the prior year[54] - The company reported cash and cash equivalents of ¥2,304,549,028.29 at the end of the quarter, up from ¥473,115,095.63 at the end of the previous year[55] - The total cash and cash equivalents at the end of the period amounted to 553,782,113.92 CNY, down from 650,012,029.04 CNY at the beginning of the period[58] - The company reported a total asset value of 5,977,153,474.43 CNY, with total liabilities amounting to 2,078,117,027.37 CNY[62] - Current assets totaled CNY 4,421,142,847.99, up from CNY 4,008,542,632.93, indicating an increase of about 10.3%[37] - Total assets at the end of the reporting period were ¥6,429,473,562.87, a 7.57% increase from ¥5,977,153,474.43 at the end of the previous year[8] Expenses and Liabilities - Operating costs rose by 104.34% year-on-year, mainly due to a significant increase in product sales volume[16] - Financial expenses increased by 56.24% year-on-year, primarily due to the amortization of interest adjustments on convertible bonds issued in 2020[18] - Credit impairment losses surged by 958.98% year-on-year, attributed to rapid growth in accounts receivable and increased bad debt provisions[19] - Sales expenses rose by 71.09% year-on-year, resulting from variable sales costs associated with revenue growth[17] - Total liabilities decreased to CNY 2,005,352,877.20 from CNY 2,078,117,027.37, a reduction of about 3.5%[39] - The total liabilities decreased to ¥970,327,125.83 from ¥1,050,446,901.44 year-over-year[46] Shareholder Information - The weighted average return on equity improved to 10.33%, an increase of 8.23 percentage points from 2.10% in the previous year[8] - Net assets attributable to shareholders increased to ¥3,474,571,447.49, up 10.62% from ¥3,140,958,791.90 at the end of the last year[8] - The total number of ordinary shareholders at the end of the reporting period was 66,399[11] - Total equity increased to ¥1,997,316,172.39 from ¥1,974,994,618.13, indicating a growth in shareholder value[46] Research and Development - Research and development expenses grew by 58.99% year-on-year, reflecting continued investment in new product development[17] - Research and development expenses rose to ¥27,385,839.26, up from ¥17,225,283.54, reflecting the company's commitment to innovation[46] Market and Future Outlook - Total revenue increased by 170.82% year-on-year, primarily due to ongoing equipment orders related to COVID-19 and a steady recovery in routine testing business[16] - The company is focusing on expanding its market presence and enhancing its product development capabilities to drive future growth[38] - The company has not provided specific user data or performance guidance for future quarters in the available documents[65][66] - There is no mention of new product development, market expansion, or mergers and acquisitions in the provided content[65][66] Miscellaneous - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[16] - The company has no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[31] - The report for the first quarter of 2021 was not audited, indicating that the figures may be subject to change[66] - The first quarter report was released on April 28, 2021, by the legal representative Zhou Qinqin[67]

Financial Performance - The company's operating revenue for 2020 was CNY 4,155,428,846.74, representing a 72.11% increase compared to CNY 2,414,471,289.30 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 675,356,413.28, a significant increase of 233.55% from CNY 202,475,418.80 in the previous year[16] - The net cash flow from operating activities reached CNY 1,367,198,250.32, marking a 449.36% increase compared to CNY 248,872,034.68 in 2019[16] - The basic earnings per share for 2020 was CNY 1.3345, up 238.10% from CNY 0.3947 in 2019[16] - The total assets at the end of 2020 amounted to CNY 5,977,153,474.43, reflecting a 61.33% increase from CNY 3,704,842,430.09 at the end of 2019[16] - The net profit after deducting non-recurring gains and losses for 2020 was CNY 658,928,540.60, which is a 258.44% increase from CNY 183,830,664.07 in 2019[16] - The company reported a weighted average return on equity of 24.76%, an increase of 15.85 percentage points from 8.91% in 2019[16] - The revenue from self-produced products amounted to ¥2,681,480,912.21, a significant increase of 145.67% from ¥1,091,489,519.78 in the previous year[66] - The international revenue surged by 283.88%, reaching ¥851,395,974.97, compared to ¥221,789,113.38 in 2019[66] - The company reported a cash dividend of ¥102,871,448.60 for the fiscal year 2020, which represents 15.23% of the net profit attributable to ordinary shareholders[128] Market Position and Strategy - The company has a total of over 260 approved diagnostic reagents and instruments, with 80 products certified by the EU CE mark[25] - The company focuses on three main diagnostic areas: immunodiagnostics, biochemical diagnostics, and molecular diagnostics, enhancing its product portfolio[25] - The company aims to become a pillar in the IVD field, emphasizing customer-centric innovation and collaboration[25] - The company has established a network of over 12,000 terminal hospitals and more than 500 high-barrier disease control centers and blood centers across 30 provinces and regions in China[29] - The company has seen a notable increase in its share of the domestic IVD market due to the shift towards domestic products amid import substitution trends[42] - The company is positioned to benefit from national policies supporting the biotechnology industry, which is recognized as a strategic emerging industry[39] - The company aims to leverage its comprehensive advantages in the in vitro diagnostic industry to drive innovation and develop new products that meet market demands[104] Research and Development - The company has established a postdoctoral research station and several technology innovation centers, reinforcing its commitment to R&D[25] - The company has over 100 ongoing research projects and has obtained 260 CFDA registration certificates and over 50 invention patents[46] - The company has made significant investments in the R&D of intelligent medical devices, particularly in its subsidiary Xi'an Tianlong[45] - Research and development expenses rose by 123.76% to CNY 146.93 million in 2020, compared to CNY 65.66 million in 2019[76] - In 2021, the company plans to enhance its R&D capabilities by increasing investment and recruiting high-tech talent, focusing on molecular and immunological fields[106] Product Development and Innovation - The company sold over 13,500 nucleic acid extraction devices and 9.1 million nucleic acid extraction reagents during the reporting period, significantly boosting sales performance[56] - The Polaris series products, including fully automated biochemical and immunoassay systems, have been launched, with the Polaris C2000 achieving a testing speed of 2,000 tests per hour[57] - The company has developed 35 new biochemical diagnostic products, 44 new chemiluminescence products, and 23 new molecular diagnostic products, all at various stages of development[59] - The company actively developed COVID-19 testing solutions, contributing to its significant sales growth during the pandemic[56] - The company has successfully registered its AIDS diagnostic products in over 30 countries, contributing significantly to global AIDS prevention efforts[187] Corporate Governance and Compliance - The company has established a quality assurance department and a regulatory affairs department to ensure timely registration of products in domestic and international markets[116] - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profit to be distributed as cash dividends, with a cumulative distribution of at least 30% over three years[123] - The company has established a comprehensive quality management system in compliance with GMP, ISO13485, and other relevant standards, ensuring rigorous quality control throughout the production process[184] - The company has maintained compliance with environmental protection laws and has not faced any significant penalties during the reporting period[190] - The company has received the AAA credit rating for contract compliance from Shanghai for several consecutive years, indicating strong financial stability and debt repayment capability[178] Social Responsibility and Community Engagement - The company actively engages in corporate social responsibility, balancing profit maximization with contributions to sustainable development and social welfare[1] - The company has actively participated in the fight against COVID-19 by donating 10,000 nucleic acid test kits to Wuhan hospitals and providing additional support to other medical institutions[188] - The company has a strong commitment to social responsibility, actively engaging in blood donation activities and supporting public health initiatives[187] Risks and Challenges - The company recognizes the ongoing risks posed by the COVID-19 pandemic, which may affect the sales of routine diagnostic products[113] - Regulatory changes in the in vitro diagnostic industry pose potential risks, necessitating close monitoring and adjustments to comply with new policies[114] - The company faces high risks in new product development due to the complex and lengthy process, which typically takes 3-5 years from project initiation to market launch[115] - The company has faced challenges in timely registration of innovative products, which could adversely affect its business plans[116] Shareholder Engagement and Financial Management - The company held 2 shareholder meetings in 2020, utilizing online voting to facilitate participation from public shareholders, especially small and medium-sized shareholders[174] - The board approved the profit distribution plan, which is subject to shareholder approval at the annual general meeting[130] - The company has not proposed any stock dividends or capital reserve transfers for the fiscal year 2020[130] - The company has not proposed any share buybacks during the reporting period[129]

Financial Performance - In Q3 2020, the company achieved a revenue of CNY 2.567 billion, representing a year-on-year growth of 45.30%[7] - The net profit attributable to shareholders reached CNY 401.83 million, up 92.90% year-on-year, while the net profit excluding non-recurring items was CNY 392.30 million, reflecting a growth of 100.95%[7] - The net cash flow from operating activities was CNY 745.61 million, an increase of 219.55% compared to the same period last year[10] - Operating revenue increased by 45.30% year-on-year, mainly due to significant growth in revenue from molecular diagnostics[17] - The total operating revenue for the third quarter was CNY 1,107,163,547.10, compared to CNY 642,632,575.21 in the previous period, indicating a significant increase[39] - The net profit for the quarter reached CNY 352,796,721.26, compared to CNY 89,290,960.67 in the same period last year, showing a substantial growth[41] - The total comprehensive income for the quarter was CNY 353,648,238.09, compared to CNY 85,774,849.01 in the same period last year, reflecting overall financial growth[42] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5.348 billion, a 44.35% increase from the previous year[10] - The total liabilities of the company amounted to CNY 1,886,553,202.39, up from CNY 1,014,343,813.31, marking a significant increase[33] - The company's equity attributable to shareholders rose to CNY 2,878,502,635.69 from CNY 2,357,108,234.92, representing an increase of approximately 22.1%[34] - The total assets as of the end of the quarter were CNY 3,100,985,638.15, compared to CNY 2,518,967,964.10 at the end of the previous period[37] - The total liabilities increased to CNY 1,170,177,076.22 from CNY 647,250,970.59, reflecting a rise in financial obligations[37] - The company's equity totaled CNY 1,930,808,561.93, up from CNY 1,871,716,993.51 in the previous period, indicating a strengthening of the financial position[37] Cash Flow and Investments - Cash and cash equivalents increased by 278.07% compared to the beginning of the year, mainly due to the issuance of convertible bonds and increased sales revenue[17] - The company reported a total of CNY 72,235.44 million in raised funds, with CNY 24,915.34 million already invested in various projects[24] - The company has allocated CNY 30,159.23 million for the construction of a chemiluminescence production line, with CNY 2,187.51 million remaining in the account[24] - The company received cash inflows from operating activities totaling ¥2,830,702,686.76, compared to ¥1,865,574,178.40 in the previous year[56] - The company’s financing activities generated a net cash inflow of ¥680,746,480.08, compared to ¥56,543,037.51 in the same quarter last year[57] Research and Development - Research and development expenses increased by 128.46% year-on-year, reflecting increased investment in the development of new products such as COVID-19 related diagnostics[17] - Research and development expenses for the quarter were CNY 27,159,723.83, significantly higher than CNY 11,647,877.86 in the previous year, highlighting a focus on innovation[40] - The company reported a significant increase in research and development expenses, indicating a focus on new product development and technology[49] Market and Product Development - The company launched the Polaris biochemical immunoassay system, which integrates biochemical and immunological analysis, enhancing automation and smart detection capabilities[8] - The company plans to continue expanding the market for its Polaris series products, which are expected to drive long-term growth[8] - The company continues to explore market expansion opportunities and new product development strategies, although specific details were not disclosed in the report[67] Shareholder Information - Total number of common shareholders at the end of the reporting period is 62,210[13] - The basic earnings per share for the reporting period was CNY 0.4062, a 199.56% increase compared to the same period last year[10] - Basic earnings per share for the current period is 0.7827, up from 0.4064 in the previous period[50] Compliance and Governance - The company did not conduct any repurchase transactions during the reporting period[14] - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[26][27] - The company has not audited the third-quarter report, indicating a potential area for investor scrutiny[70] - The company is implementing new revenue and leasing standards starting in 2020, which may affect future financial reporting[70]

上海科华生物工程股份有限公司 2020 年半年度报告全文 上海科华生物工程股份有限公司 2020 年半年度报告 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质性承诺，投资者及相关人士应 当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异。 2020 年 08 月 1 | 第一节 | 重要提示、目录和释义 | 3 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 公司业务概要 | 8 | | 第四节 | 经营情况讨论与分析 11 | | | 第五节 | 重要事项 | 20 | | 第六节 | 股份变动及股东情况 | 26 | | 第七节 | 优先股相关情况 | 31 | | 第八节 | 可转换公司债券相关情况 | 32 | | 第九节 | 董事、监事、高级管理人员情况 | 33 | | 第十节 | 公司债相关情况 | 35 | | 第十一节 | 财务报告 | 36 | | 第十二节 | 备查文件目录 | 139 | 上海科华生物工程股份有限公司 2020 年半年度报告全文 第一节 ...

上海科华生物工程股份有限公司 2019 年年度报告全文 上海科华生物工程股份有限公司 2020 年 04 月 2019 年年度报告 1 | 第一节 | 重要提示、目录和释义 | 3 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 公司业务概要 | 9 | | 第四节 | 经营情况讨论与分析 | 14 | | 第五节 | 重要事项 | 27 | | 第六节 | 股份变动及股东情况 | 41 | | 第七节 | 优先股相关情况 | 48 | | 第八节 | 可转换公司债券相关情况 | 49 | | 第九节 | 董事、监事、高级管理人员和员工情况 | 50 | | 第十节 | 公司治理 | 57 | | 第十一节 | 公司债券相关情况 | 63 | | 第十二节 | 财务报告 | 64 | | 第十三节 | 备查文件目录 | 181 | 上海科华生物工程股份有限公司 2019 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和 ...

上海科华生物工程股份有限公司 2020 年第一季度报告全文 上海科华生物工程股份有限公司 2020 年第一季度报告 2020 年 04 月 1 上海科华生物工程股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人胡勇敏、主管会计工作负责人罗芳及会计机构负责人(会计主管人员)王强声明：保证季度 报告中财务报表的真实、准确、完整。 2 上海科华生物工程股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 上海科华生物工程股份有限公司（以下简称"科华生物"、"公司"）是一家立足于精准医疗领域，拥有完整 医疗诊断产品及整体解决方案的中国体外诊断公司。作为首家登陆深圳证券交易所中小板的体外诊断上市公司， 始终坚持仪器和试剂双轮驱动，是国内为数不多的能够在分子、生化及免疫等领域，均具备全自动、灵活通量 检测系统解决方案和供应能力的公司，在国内体外临床诊断行业中拥有显著 ...

上海科华生物工程股份有限公司 2019 年第三季度报告全文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人胡勇敏、主管会计工作负责人罗芳及会计机构负责人(会计主管人员)王强声明：保证季度 报告中财务报表的真实、准确、完整。 上海科华生物工程股份有限公司 2019 年第三季度报告 2019 年 10 月 1 上海科华生物工程股份有限公司 2019 年第三季度报告全文 第一节 重要提示 第二节 公司基本情况 一、主要会计数据和财务指标 报告期内，公司紧密围绕既定的发展战略目标，专注主营业务，聚焦优势领域，重视技术创新和产品研发，丰富公司产 品线，坚持"以产品为核心，以市场为导向"的发展观，持续内部挖潜，优化资源配置。年初至报告期末，公司实现营业总 收入 176,703 万元，同比增长 20.03%；实现归属于母公司所有者的净利润 20,831 万元，同比增长 3.75%。经营活动现金流 量净额 23,333 万元，同比增长 902.92%。由于并购投资活 ...